Although immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies of lung cancer, the overall response rate of ICI monotherapies is still limited and no more than 20% in NSCLC patients with EGFR/ALK wild-type (Doroshow et al., 2019). This evidence concerns the gene ALK and non-small cell lung carcinoma.